Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deulorlatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Simcere Zaiming
Deal Size : $20.0 million
Deal Type : Collaboration
Simcere Zaiming Collaborates with TargetRx to Introduce a Third-Generation ALK inhibitor
Details : Simcere Zaiming will acquire exclusive commercial rights to TGRX-326, an ALK/ROS1 dual receptor tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC), in Mainland China.
Product Name : TGRX-326
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
February 09, 2024
Lead Product(s) : Deulorlatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Simcere Zaiming
Deal Size : $20.0 million
Deal Type : Collaboration
Reset All
